Discover and read the best of Twitter Threads about #arvm2019bris

Most recents (2)

☣First up for the final session is ☣Nathan Bartlett (…), Hunter Medical Research Institute, Uni of Newcastle, NSW talking on TLR2 agonist treatment suppresses rhinovirus infection of human epithelial cells in vitro

☣modify host immunity to tackle *any* virus; boost innate immunity
☣grand plan
☣TLR the sentinel activators/regulators of innate immunity
☣any old virus can be a huge problem if you are immunosuppressed (vax less effective)
☣TLRs on the surface facing out, and those inside in endosomes (the antiviral TLRs) inducing lots of IFN and inflammation
☣used as a last resort to avoid immunopathology that can be associated with their activation; too inflammatory
Read 9 tweets
⬛ after tea Tejasri Yarlagadda, from @QUT on a pilot study investigating viral pathogenesis of otitis media (OM): epithelial Immunity and therapeutic targets
⬛OM a significant cause of morbidity, antibiotic prescriptions and surgery ($400mill cost in AUS annually)
@QUT ⬛ since viruses are the basis of OM aetiology, antibiotics aren't helpful (for that stage)
⬛what about recurrent or chronic OM.
⬛Acute OM (AOM) considered to be viral infection followed by expansion of colonising bacteria
⬛persistent viral infection role?
@QUT ⬛study screened nasal swabs ad found viruses in OM probe an non-robe kids
⬛ but TOTAL number of infection was double that in prone group, often as co-infections
⬛primary airway epithelial cell culture model at air-liquid interface (ALI)
Read 7 tweets

Related hashtags

Did Thread Reader help you today?

Support us! We are indie developers!

This site is made by just three indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3.00/month or $30.00/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!